Key Highlights

• Gilead Sciences' $0.82 quarterly Dividend trades ex-date September 15, 2026, payable September 29, yielding approximately 2.27%.

• Second-quarter Revenue reached approximately $7.8 billion, with product sales excluding Veklury up 10% and HIV sales up 12%, though GAAP diluted loss per share was $(8.45).

• The reported loss was driven by $(9.08) per share of acquired IPR&D and tax expenses tied to the Arcellx, Tubulis and Ouro Medicines acquisitions; illustrative EPS excluding those effects was $2.27.

• The company opened a new 182,000-square-foot Research Center in Foster City on September 8, part of a planned $32 billion U.S. Investment through 2030.

Gilead Sciences' (NASDAQ:GILD) $0.82 quarterly dividend yields approximately 2.27%, a payout that remains well supported by recurring cash generation despite a headline GAAP loss this quarter. The more consequential story is understanding what actually drove that $(8.45) per share reported loss: $(9.08) per share of acquired in-process Research and Development and associated tax expenses tied to the Arcellx, Tubulis and Ouro Medicines acquisitions, meaning Gilead's illustrative EPS excluding those acquisition-related effects was actually a healthy $2.27, a figure that far better reflects the company's underlying commercial performance.

Dividend Program and Shareholder Returns

Gilead declared a $0.82 per share quarterly dividend for the third quarter of 2026, payable September 29 to shareholders of record September 15. The annualized regular dividend is $3.28 per share. The dividend is supported primarily by recurring Operating Cash Flow from Gilead's commercial product portfolio rather than by GAAP net income, which fluctuates substantially with acquisition, licensing and Impairment charges.

About the Company

Gilead Sciences is a global biopharmaceutical company focused on HIV, viral hepatitis, oncology and inflammation, historically generating substantial cash flow from its HIV and hepatitis franchises that funds research, acquisitions, licensing and shareholder returns.

Financial Performance Behind the Payout

Gilead reported second-quarter revenue of approximately $7.8 billion, with product sales excluding Veklury increasing 10% year over year to approximately $7.6 billion. Biktarvy sales increased 7% to approximately $3.8 billion, while total HIV sales grew 12% to $5.693 billion. Trodelvy sales in oncology increased 26% to $457 million. GAAP diluted loss per share was $(8.45), and non-GAAP diluted loss per share was $(6.75), primarily reflecting $(9.08) per share of acquired IPR&D and tax expenses associated with the Arcellx, Tubulis and Ouro Medicines acquisitions; excluding those acquisition-related effects, illustrative non-GAAP diluted EPS was $2.27. Management raised full-year base Business product sales guidance to $29.8-$30.1 billion.

Reported Losses Reflect Acquisition Accounting, Not Commercial Weakness

Gilead's headline losses this quarter are almost entirely an artifact of acquisition accounting rather than any deterioration in the underlying commercial business, which delivered its strongest second-quarter base business growth in three years according to management. HIV sales growth of 12%, driven by continued treatment strength and rapid PrEP expansion, alongside Trodelvy's 26% oncology growth and Livdelzi's contribution to a 10% rise in the Liver Disease portfolio, demonstrates genuine multi-franchise commercial momentum. The new Foster City Research Center, opened September 8 as part of Gilead's planned $32 billion U.S. investment through 2030 supporting approximately 3,000 domestic jobs, signals continued reinvestment in the pipeline that is expected to eventually offset the near-term dilution from recent large acquisitions.

Outlook

Gilead's dividend is well supported by strong recurring commercial cash flow, with the current GAAP losses reflecting acquisition-related accounting rather than any threat to the underlying business generating that cash. Investors should watch base business revenue growth across HIV, oncology and liver disease franchises, pipeline progress from the Arcellx, Tubulis and Ouro Medicines acquisitions, and the trajectory of illustrative EPS excluding acquisition effects as a cleaner measure of commercial performance.